• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TENOFOVIR Drug Record

  • Summary
  • Interactions
  • Claims
  • TENOFOVIR chembl:CHEMBL483

    Alternate Names:

    GS-1275
    ATRIPLA
    TRUVADA
    TENOFOVIR
    PMP-A
    ANH. TENOFOVIR
    TENOFOVIR (ANH.)
    TENOFOVIR ANHYDROUS
    TENOFOVIR DISOPROXIL
    VIREAD
    PMPA
    TDF
    (R)-9-(2-PHOSPHONOMETHOXYPROPYL)ADENINE
    ANHYDROUS TENOFOVIR
    GS-1278
    (R)-PMPA
    rxcui:117466
    drugbank:14126
    rxcui:1546017
    chembl:CHEMBL483
    chemidplus:147127-20-6
    pubchem.compound:464205

    Drug Info:

    (0 More Sources)

    Publications:

    Pushpakom SP et al., 2011, Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction., J Infect Dis
    Bleasby K et al., 2005, Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6)., J Pharmacol Exp Ther
    Weiss J et al., 2007, Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors., Drug Metab Dispos
    Cusato J et al., 2020, Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients., Pharmacogenomics J
    Likanonsakul S et al., 2016, A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection., PLoS One
    Nishijima T et al., 2015, Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study., PLoS One
    da Rocha IM et al., 2015, Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort., Pharmacogenet Genomics
    Dahlin A et al., 2015, A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome., Pharmacogenet Genomics
    Rodríguez-Nóvoa S et al., 2009, Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study., Clin Infect Dis
    Izzedine H et al., 2006, Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy., J Infect Dis
    Baxi SM et al., 2018, Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV., Pharmacogenomics J
  • TENOFOVIR   OCRL

    Interaction Score: 10.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25485598


    Sources:
    PharmGKB

  • TENOFOVIR   SLC26A8

    Interaction Score: 5.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TENOFOVIR   AK4

    Interaction Score: 5.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TENOFOVIR   AK2

    Interaction Score: 5.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TENOFOVIR   ABCC10

    Interaction Score: 2.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21628669


    Sources:
    PharmGKB

  • TENOFOVIR   NME2

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TENOFOVIR   NME1

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TENOFOVIR   SLC22A6

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15914676


    Sources:
    PharmGKB

  • TENOFOVIR   ABCC2

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31619748 26807589 26535588 26287941 25485598 19400747 17083032 17172311


    Sources:
    DTC PharmGKB

  • TENOFOVIR   ABCC3

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17172311


    Sources:
    DTC

  • TENOFOVIR   ABCC1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17172311


    Sources:
    DTC

  • TENOFOVIR   ABCG2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28462920


    Sources:
    PharmGKB

  • DTC: TENOFOVIR

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL483 ChEMBL Drug ID

    Drug Info:

    Publications:
    Weiss J et al., 2007, Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors., Drug Metab Dispos

  • PharmGKB: tenofovir

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Bleasby K et al., 2005, Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6)., J Pharmacol Exp Ther
    Baxi SM et al., 2018, Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV., Pharmacogenomics J
    Cusato J et al., 2020, Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients., Pharmacogenomics J

  • TTD: Tenofovir

    • Version: 2020.06.01

    Alternate Names:
    D0D9HW TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL483

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21